KDM5B and cancer: Novel epigenetic targets identified in cancers have given rise to the next generation of epigenetic therapies that include enhancer of zest homolog 2 inhibitors (EZH2i), bromodomain, and extra-terminal domain inhibitors (BETi), inhibitors of the demethylases JMJD3 and JARID1B, as well as many other compounds [202].